This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wei, Q. Articles by Carlsson, J. Search for Related Content PubMed PubMed Citation Articles by Wei, Q. Articles by Carlsson, J.

EGFR, HER2, and HER3 Expression in Laryngeal Primary Tumors and Corresponding Metastases

¹ Department of Radiation Oncology, The Second Affiliated Hospital; and Cancer Institute, Zhejiang University School of Medicine, Jiefang Road 88, Hangzhou, 310009, P. R. China
² Cancer Institute, Zhejiang University, Hangzhou, 310009, China
³ Department of Oncology, Radiology and Clinical Immunology, Rudbeck Laboratory, Uppsala University Hospital, SE-751 85, Uppsala, Sweden
⁴ Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University Hospital, SE-751 85, Uppsala, Sweden

Correspondence: Address correspondence and reprint requests to: Qichun Wei, MD, PhD; E-mail: Qichun_Wei{at}zju.edu.cn

Background: There are several substances available to target members of the epidermal growth factor receptor (EGFR) family, both for imaging in nuclear medicine and for various forms of therapy. The level and stability of expression in both primary tumors and corresponding metastases is crucial in the assessment of a receptor as a target in systemic tumor therapy. To date, the expression of EGFR family members has only been determined in primary laryngeal carcinomas, and we have not found published data regarding the receptor status in corresponding metastatic lesions.

Methods: Expression of EGFR, HER2, and HER3 was investigated immunohistochemically in both lymph node metastases and corresponding primary laryngeal squamous carcinomas (n = 40).

Results: EGFR overexpression (2+ or 3+) was found in 87.5% (35/40) of the laryngeal primary tumors and 82.5% (33/40) of the corresponding lymph node metastases. There was a good agreement between the primary tumors and the paired metastases regarding EGFR expression. HER2 overexpression was found in only four cases (10.5%) of the studied primary tumors and in all cases the HER2 expression was retained in the paired metastases. Another two metastases gained HER2 status when compared to the corresponding primary tumors. Strong HER3 staining was found in 26.7% of both the primary tumors and the corresponding metastases.

Conclusions: The high frequency and stability in EGFR expression is encouraging for efforts to use EGFR targeting agents (e.g. Iressa, Tarceva, Erbitux or radiolabeled antibodies) for therapy of laryngeal carcinoma. For a few laryngeal carcinoma patients with HER2 overexpression, anti-HER2 agents could possibly be used.

Key Words: Laryngeal carcinoma • EGFR • HER2 • HER3 • Metastasis • Receptor overexpression

This article has been cited by other articles:

				M. Hayashi, M. Inokuchi, Y. Takagi, H. Yamada, K. Kojima, J. Kumagai, T. Kawano, and K. Sugihara High Expression of HER3 Is Associated with a Decreased Survival in Gastric Cancer Clin. Cancer Res., December 1, 2008; 14(23): 7843 - 7849. [Abstract] [Full Text] [PDF]